Research Commercialization Academy (BETA 0.01)

Back Office Services for

UTS Penn State PDF Print E-mail

University Technology Showcase Webinar Series

Technology Transfer at The Pennsylvania State University

Tuesday, 6 December 2011, 1:00-2:30 PM EST   




About this Webinar:

The Office of Technology Development

The Office of Technology Development (OTD) serves the Penn State College of Medicine and Penn State Milton S. Hershey Medical Center faculty and staff, and the scientific and business communities.  OTD’s focus is on fostering an ecosystem for technology innovation and translation; the successful marketing of Penn State intellectual property and licensing to corporations and to start-up companies.

Services to Industry:

  • Listen to your needs and discover Penn State licensable technologies that your company can utilize.
  • Screen inventions and discoveries made in University facilities for patentability, commercial potential, and general marketability.
  • Review and update lists of licensable technologies and patents issued, and post on our Web site.
  • Foster the creation and development of start-up companies.
  • Providing education on entrepreneurship, innovation and commercialization to students and faculty
  • Negotiate licensing arrangements.

For more information, please contact Dr. Keith Marmer, Associate Dean for Technology Innovation at the Penn State Hershey College of Medicine, This e-mail address is being protected from spambots. You need JavaScript enabled to view it , 717-531-8496


Time Presentation Presenter

Apeliotus Vision Science, Inc.
(Download Executive Summary) (Download Presentation Slides)


AMD is the leading cause of adult blindness in developed countries. It affects over 30 million people worldwide, including one in six over age 65 and one in three over age 75. Frost & Sullivan estimates the annual market for AMD diagnosis and treatment will grow to $7 billion per year. Despite the tremendous value of early detection, there is currently no good means for diagnosis before significant vision loss has occurred.


The AdaptDx is a simple, sensitive diagnostic instrument based on measurement of dark adaptation (the recovery of vision when going from bright light to darkness). It can detect and track AMD from its earliest stages allowing early intervention. Testing can be performed by an unskilled operator in 10 minutes or less.

Presenter – John Edwards, CEO

MelanomeX Oncology, Inc:  Late Stage Melanoma Treatment
(Download Executive Summary) (Download Presentation Slides)


The World Health Organization reports an average of 160,000 new cases of melanoma every year.  Approximately 48,000 fatalities are reported every year due to melanoma.  The Nanolipolee-007 drug has potential to affect the entire market and present new options to patients.

The Product/Project Type

Nanolipolee-007 is a Chemotherapeutic that has been shown to be effective in slowing or even stopping the progression of melanoma development in pre-clinical animal models.  The current focus on conducting IND enabling preclinical studies will lead to submission of an IND and a Phase 1 trial.  

Presenter – Thomas Lytle, Interim CEO

NuHope: Brain Tumor Treatment
(Download Executive Summary)
(Download presentation slides - this slide deck included presentations of NuHope, Multipurpose Ophtalmic and PDQ)


Approximately 25,000 people develop Temodar (The main compound used to reduce the tumor) resistant brain tumors.  Survival ranges on average between 14 – 16 months.  The market value for Temodar resistant tumor treatment is about $250 million per year.  However, given the effectiveness and safety profile of the new compound, the drug has the potential to become the preferred frontline treatment for both Temodar resistant and non-resistant tumors.  The total market value for all brain tumor treatment is forecasted to be $1.3 billion per year.

The Product/Project Type

The lead compound is extremely effective and shows safety profiles in a mouse orthotopic model of brain tumors.  The compound was extremely effective in tamodar resistant cells as well.  Temodar is currently the standard care for brain tumors.  The current focus is leading toward a Phase 1 clinical trial.   

Presenter – Chandra Rao, Business Specialist, Office of Technology Development, Penn State College of Medicine


Multipurpose Ophthalmic Microsurgical Simulator
(Download Executive Summary)


Intricacies of ocular surgery have changed over the last 30 years.  The need for sutures in the eye has decreased in amount but has increased in complexity.  Currently ophthalmology students and practitioners do not have the experience in complex sutures and ocular procedures necessary to complete surgical operations using new methodologies.      Using the Multipurpose Ophthalmic Microsurgical Simulator, students, practitioners, and military personnel will be better trained in new methodologies treating ocular conditions and traumatic injuries

The Product/Project Type

The Multipurpose Ophthalmic Microsurgical Simulator is used for teaching and refreshing microsurgical skills in the repair of wounds involving the cornea or sclera of the eye.  However, the instrument is sufficiently flexible so that, with minor modification, it can be utilized to simulate other microsurgical and non-microsurgical procedures.

Specific features of the design include: a mannequin head covered by unique model skin, and containing the base unit housing a novel tracking system for two universal instruments that containing the complementary components of the tracking system, and when coupled with appropriate graphics, can simulate various surgical instruments.  Other hardware components include a modified commercial microscope control pedal, and two LCD displays (one touch screen for data entry and one for stereoscopic viewing).

Specific software components include the rendering of the virtual patient head and surgical field, simulating microscope actions including X-Y translocation, zoom and focus, knot tying simulation, and teaching enhancements.  The principals are additionally focused on expanding the system capabilities for simulation of numerous other body segments by leveraging the current elements of the system and intellectual property.

Presenter – Chandra Rao, Business Specialist, Office of Technology Development,

Penn State College of Medicine



PDQ: Physician Directed Queuing
(Download Executive Summary)


The United States healthcare delivery system is broken. Nowhere is that more evident than in emergency rooms across the country.  Emergency patients spend an average of 4 hours and 5 minutes in the emergency department. ‘Boarding,’ the extended stay of a patient in the emergency department until a hospital bed becomes available exacerbates this wait time. Hundreds of emergency departments have closed in the U.S. in recent years while at the same time emergency room visits have increased considerably; 123.8 million in 2010. According to the American Hospital Association, 47% of hospitals are operating at or over capacity, and 10% of hospitals are so crowded they divert patients arriving by ambulance at least 20% of the time. Hospital crowding of emergency departments is associated not only with less timely care and increased patient dissatisfaction but also with less effective care and poorer outcomes. A result of the above is that greater than 50% of hospital emergency departments across the nation are experiencing a crisis in profitability.

Outcome measures based on PDQ resulted in an 83% reduction in average wait time, a 44% increase in total annual visits and a 400% improvement in patient satisfaction – all accomplished with a 65% smaller investment than originally predicted. The implementation of PDQ resulted in approximately $25 million in increased annual revenue from the emergency department without any increase in incremental staffing or expenses.


The Product/Project Type

This project includes the holistic use of sophisticated Industrial Engineering process optimization techniques within Emergency Departments.  Queuing theory was used to analyze ED throughput and to identify inefficiencies. Front-end admission processes are mapped to understand workflow and identify bottlenecks.  After implementation of the PDQ model, average wait time, median door-to-doctor time, median door-to-bed time, and median length of stay were all significantly reduced.


Presenter – Chandra Rao, Business Specialist, Office of Technology Development,

Penn State College of Medicine


COST OF THE WEBINAR: Free, but registration required by clicking on the link above.

This series is online. You need a computer with web access for the visual/audio. Q&A is conducted by a chat box to the speakers. Once registered to the webinar series you will receive a separate email with the webinar url 24 hours before the start of the webinar.

Angel investors, venture capitalists, large companies, entrepreneurs, SBIR companies, federal lab researchers, federal agency representatives, and others who want to learn more about the research program highlighted during the webinar.

SLIDES AND VIDEO: The slide presentations and video recording will be available on this page. The slide presentations will be available for download shortly before the webinar. The video recording of this webinar will be available within 24 hours after the scheduled webinar ends.

  • Kamagra Online
  • Viagra Online
  • Cialis Online
  • Levitra Online
  • Zithromax Online
  • Propecia Online
  • Amoxil Online
  • Priligy Online
  • Lasix Online